Small molecule · Antagonist of androgen receptor (AR) · developed by Astellas
ApprovedFDA, Aug 2012
1Registered trials
What is Enzalutamide?
Enzalutamide is an oral androgen receptor inhibitor that competitively blocks androgen binding, prevents nuclear translocation of the receptor and its interaction with DNA. It is studied in and used for prostate cancer, including castration-resistant and castration-sensitive disease.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Xtandi, MDV-3100
Drug type
Small molecule
Targets
androgen receptor (AR)
Mechanism
Antagonist of androgen receptor (AR)
Pathways
androgen receptor signaling, androgen binding and nuclear translocation, androgen receptor DNA interaction
Non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis
From the indications section of the FDA label (version of Jul 28, 2026). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.